本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

VWR International

33.25
+0.0000
成交量:- -
成交額:- -
市值:43.78億
市盈率:29.69
高:33.25
開:33.25
低:33.25
收:33.25
資料載入中...

公司資料

公司名字:
VWR International
交易所:
NASDAQ
成立時間:
- -
員工人數:
- -
公司地址:
- -
官網:
- -
郵編:
- -
電話:
- -
傳真:
- -
簡介:
VWR Corp operates primarily in the global life science, general research and applied markets, which include customers in the traditional pharmaceutical sector as well as the biotechnology sector (collectively referred to as “Biopharma”), as well as industries such as agriculture, chemical, environmental, food and beverage, healthcare, microelectronic and petrochemical. Our product offering to these customers has primarily consisted of laboratory products, which we estimate generated $39 billion of global sales in 2013 based on Frost & Sullivan estimates, and continues to be our largest single market. According to Frost & Sullivan, the global laboratory products market is projected to continue to expand by approximately 2% annually through 2015. We recently began offering additional complex value-added services in the laboratory services market, which Frost & Sullivan estimated in a study commissioned by us to be approximately $4 billion in 2013 and growing in the high single to low teens digits. We have also expanded our internal bioprocess chemicals and consumables manufacturing business, which provides products and chemicals used in the production of biopharmaceuticals, diagnostics and other products, both through organic efforts and through targeted acquisitions. In a study commissioned by us, Frost & Sullivan estimated the bioprocess chemicals and consumables market to be approximately $6 billion in 2013 and growing at approximately 10% to 12% annually. Further, we are expanding our offering of products and services in sectors such as certain production and industrial segments. As a result of the addition of these new services and customer categories, we believe we have expanded our total addressable market.,We operate primarily in the global life science, general research and applied markets, which include customers in the traditional pharmaceutical sector as well as the biotechnology sector (collectively referred to as “Biopharma”), as well as industries such as agriculture, chemical, environmental, food and beverage, healthcare, microelectronic and petrochemical. Our product offering to these customers has primarily consisted of laboratory products, which we estimate generated $39 billion of global sales in 2013 based on Frost & Sullivan estimates, and continues to be our largest single market. According to Frost & Sullivan, the global laboratory products market is projected to continue to expand by approximately 2% annually through 2015. We recently began offering additional complex value-added services in the laboratory services market, which Frost & Sullivan estimated in a study commissioned by us to be approximately $4 billion in 2013 and growing in the high single to low teens digits. We have also expanded our internal bioprocess chemicals and consumables manufacturing business, which provides products and chemicals used in the production of biopharmaceuticals, diagnostics and other products, both through organic efforts and through targeted acquisitions. In a study commissioned by us, Frost & Sullivan estimated the bioprocess chemicals and consumables market to be approximately $6 billion in 2013 and growing at approximately 10% to 12% annually. Further, we are expanding our offering of products and services in sectors such as certain production and industrial segments. As a result of the addition of these new services and customer categories, we believe we have expanded our total addressable market.